Please assess the completion status of the following clinical trial:

Trial Title: The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Population (base) RA patients of 65 years of age and older requiring antirheumatic therapy.~Inclusion criteria~In order to be eligible to participate in this study, a subject must meet all of the following criteria:~* RA according to the 1987 or the 2010 classification criteria of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) (Aletaha D et al, Ann Rheum Dis 2010;69:1580);~* inadequate disease control, as evidenced by a disease activity score of 28 joints calculated with erythrocyte sedimentation rate (DAS28) ≥2.60;~* age ≥ 65 years.~Exclusion criteria~A potential subject who meets any of the following criteria will be excluded from participation in this study:~Lower probability of benefit:~* Change, stop or start of antirheumatic treatment in the last month prior to eligibility assessment, including methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, azathioprine, intramuscular and oral gold, cyclosporine, biologic agents including anti-tumor necrosis factor (TNF), anakinra, abatacept, rituximab, tocilizumab (temporary exclusion);~* Treatment with systemic GC: oral or parenteral GC with a cumulative prednisolone equivalent dose of 200 mg or higher in the last 3 months;~* Treatment with any GC (oral, intra-articular, intravenous or intramuscular) in the last 30 days (temporary exclusion);~* Note: as this is a pragmatic trial, patients who require start of (other) antirheumatic treatment at baseline or during the trial can still be eligible (see 7.1).~Higher probability of harm:~* Exposure to investigational therapy in the last three months;~* Current participation in another clinical trial;~* Major surgery, donation or loss of approximately 500 ml blood within 4 weeks prior to the screening visit (temporary exclusion)~* Absolute contraindication to low-dose prednisolone, as determined by the treating physician, such as: uncontrolled chronic infections, diabetes mellitus, hypertension, osteoporosis. When these conditions are under control (e.g. with antiosteoporosis drugs, antihypertensive drugs) these patients can enter;~* Absolute contraindication to Calcium and/or Vitamin D supplement as determined by the treating physician, such as: hyperparathyroidism (when insufficiently treated);~* Uncontrolled comorbid conditions, short life span, etc. as determined by the treating physician.~Difficulty to measure harm/benefit:~* Absolute indication to start with oral or intravenous GC, according to the treating physician;~* Inability to comply with medical instructions or inability to assess major outcomes at 6-monthly visits, in the assessment of the treating physician.~Subjects/patients not capable or willing to provide informed consent.~Substudy~Additional exclusion criteria for subjects participating in the substudy to measure the effect of a reminder via smart device on adherence:~Inability/difficulty to measure benefit:~* Not in the possession of a smart device;~* Premature discontinuation of study medication within or at 3 months of the main trial.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- prednisolone (Type: EXPERIMENTAL): prednisolone 5 mg per day
- placebo (Type: PLACEBO_COMPARATOR): placebo capsules once per day

Based on this trial design, predict the completion outcome and termination type (if applicable).